CAR-T treatment for CD70-positive advanced solid tumors
Part of Cancer clinical trials.
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 75, and you expect to live more than 3 months.
- Your cancer is an advanced or metastatic solid tumor and has failed standard first treatment (or has no standard option).
- Your tumor must be CD70-positive, with enough CD70 protein level (at least 30% on testing).
- You must have at least one measurable tumor spot that can be tracked on scans.
- You can provide a fresh or stored tumor tissue sample (from the last 6 months) and agree to possible repeat biopsy.
- Your blood counts and organ tests (liver, kidneys, etc.) must be strong enough for treatment, and you must have a good enough energy level (ECOG 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-NKT cells) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments.
This trial tests a new type of immune cell therapy (NKG2D CAR-T cells) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if these specially engineered cells can shrink tumors or slow their growth.
This trial tests a new type of CAR-T cell therapy designed to target two proteins, CD73 and AXL, found on cancer cells. It is for people with advanced or metastatic solid tumors (like bile duct, pancreatic, lung, breast, head and neck, or gynecologic cancers) who have not responded to standard treatment or have no standard first-line therapy available.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
This trial tests a new CAR T-cell therapy made from your own immune cells to treat advanced cancers that have not responded to other treatments. It may be an option if your tumor has a specific target and you are otherwise healthy enough.
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.